PMID: 7545060Jun 1, 1995Paper

Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group

The British Journal of Psychiatry : the Journal of Mental Science
J Peuskens

Abstract

This study was performed in order to evaluate the short-term efficacy and safety of fixed risperidone doses compared to haloperidol. In a multi-national, parallel-group, double-blind study, patients with chronic schizophrenia (DSM-III-R) were randomly assigned to risperidone 1, 4, 8, 12 or 16 mg or haloperidol 10 mg daily for 8 weeks. Efficacy was assessed by the Positive and Negative Syndrome Scale for schizophrenia (PANSS) and clinical global impression (CGI), and safety primarily by the Extrapyramidal Symptom Rating Scale (ESRS). One thousand three hundred and sixty-two patients were evaluated. The optimum risperidone doses were 4 mg and 8 mg, with response rates of 63.4% (56.8%; 69.7%) and 65.8% (59.2%; 71.9%) respectively. Response rate in haloperidol-treated patients was 58.7% (52.0%; 65.3%); the 95% confidence intervals (CI) of the differences between risperidone 4 mg or 8 mg and haloperidol were (- 4.3%; 13.7%) and (- 1.9%; 16.0%) respectively. There were no significant differences in CGI scores at endpoint between risperidone 4 mg, 8 mg, 12 mg and 16 mg and haloperidol (3.0, 3.0, 3.2, 3.1 and 3.1 respectively); the 95% CI of the differences between risperidone 4 mg or 8 mg and haloperidol were ( - 0.4; 0.1) and ( - 0.3...Continue Reading

References

Jun 1, 1992·Seminars in Arthritis and Rheumatism·P Tugwell
Sep 1, 1990·Pharmacopsychiatry·Y G GeldersP A Janssen
Jan 1, 1990·Schizophrenia Bulletin·S R Kay, S Sevy
Aug 1, 1990·Archives of General Psychiatry·T Van PuttenJ Mintz
Jan 1, 1985·Schizophrenia Bulletin·T J Crow
Jan 1, 1988·Archives of General Psychiatry·R J BaldessariniM H Teicher
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1985·Psychopharmacology·D L CeulemansP A Janssen
Apr 1, 1985·The American Journal of Psychiatry·R E Drake, J Ehrlich
Jul 1, 1974·Archives of General Psychiatry·T Van Putten
Nov 1, 1984·Archives of General Psychiatry·T Van PuttenS R Marder
Aug 1, 1983·Journal of Clinical Psychopharmacology·M K ShearP Weiden

❮ Previous
Next ❯

Citations

Dec 5, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·E MohrP P De Deyn
May 1, 1997·Journal of Clinical Pharmacology·P F Buckley
Mar 20, 2004·Irish Journal of Medical Science·J V Lucey, S E Libretto
Jan 1, 1997·European Archives of Psychiatry and Clinical Neuroscience·H J MöllerH Schubert
Jan 12, 2012·Psychopharmacology·Philippe CorbeilEmmanuelle Pourcher
Jan 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·G BondolfiH Dufour
Jan 1, 1996·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·R G McCreadie
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yung-Chieh YenMian-Yoon Chong
Apr 20, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Claire AdvokatJoseph E Comaty
Jan 10, 2002·European Journal of Pharmacology·P S Naidu, S K Kulkarni
Feb 20, 2003·European Journal of Pharmacology·Rakesh KumarBhola N Dhawan
Oct 30, 1998·Journal of Psychiatric Research·M D Jibson, R Tandon
Jan 4, 1998·Pharmacology, Biochemistry, and Behavior·T FukuokaM Matsuo
Apr 2, 1998·Clinical Therapeutics·A DaviesI Schweitzer
Jun 6, 2003·Neuroscience and Biobehavioral Reviews·Albert Hung Choy Wong, Hubert H M Van Tol
Jul 10, 2003·General Hospital Psychiatry·Naoshi HorikawaKiyoshi Takamatsu
Dec 31, 2002·Archives of Medical Research·Murad AtmacaOmer Gecici
Oct 21, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·G SechiG Rosati
Dec 23, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Frank-Gerald Pajonk
Dec 31, 2002·Psychoneuroendocrinology·R Tandon, M D Jibson
Dec 31, 2002·Psychoneuroendocrinology·A J Cutler
Dec 31, 2002·Psychoneuroendocrinology·H Nasrallah
Nov 5, 2002·Schizophrenia Research·Herbert Y MeltzerKaruna Jayathilake
Nov 5, 2002·Schizophrenia Research·Tomiki SumiyoshiHerbert Y Meltzer
Feb 20, 2003·Schizophrenia Research·Teresa J HudsonCarol R Thrush
May 27, 2003·Schizophrenia Research·Tomiki SumiyoshiHerbert Y Meltzer
Aug 2, 2003·Schizophrenia Research·Rahul GangulyBradley C Martin
Apr 26, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·R Bullock, S Libretto
Sep 1, 1998·European Psychiatry : the Journal of the Association of European Psychiatrists·P BechA Claus
Jan 1, 1998·European Psychiatry : the Journal of the Association of European Psychiatrists·D King
Jan 1, 1998·European Psychiatry : the Journal of the Association of European Psychiatrists·J PeuskensM De Hert
Jun 29, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M M MarcusT H Svensson
Sep 5, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·A Aleman, R S Kahn
Oct 6, 2001·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J M Kane

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here